Regression of hypertensive left ventricular hypertrophy by Losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial Academic Article uri icon

Overview

MeSH Major

  • Adrenergic beta-Antagonists
  • Angiotensin II Type 1 Receptor Blockers
  • Atenolol
  • Hypertension
  • Hypertrophy, Left Ventricular
  • Losartan

abstract

  • Antihypertensive treatment with losartan, plus hydrochlorothiazide and other medications when needed for pressure control, resulted in greater LVH regression in patients with ECG LVH than conventional atenolol-based treatment. Thus, angiotensin receptor antagonism by losartan has superior efficacy for reversing LVH, a cardinal manifestation of hypertensive target organ damage.

publication date

  • September 14, 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1161/01.CIR.0000141573.44737.5A

PubMed ID

  • 15326072

Additional Document Info

start page

  • 1456

end page

  • 62

volume

  • 110

number

  • 11